(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 41.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Ac Immune Sa's revenue in 2025 is $35,701,234.On average, 5 Wall Street analysts forecast ACIU's revenue for 2025 to be $411,682,546, with the lowest ACIU revenue forecast at $226,324,990, and the highest ACIU revenue forecast at $632,585,375. On average, 5 Wall Street analysts forecast ACIU's revenue for 2026 to be $4,623,094,578, with the lowest ACIU revenue forecast at $1,349,816,698, and the highest ACIU revenue forecast at $9,488,780,627.
In 2027, ACIU is forecast to generate $10,411,551,991 in revenue, with the lowest revenue forecast at $9,231,930,882 and the highest revenue forecast at $11,545,185,147.